Compare HDFC Bank Limited Common Stock (HDB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HDFC Bank Limited Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? HDFC Bank Limited Common Stock trades at $23.1 (market cap $114.94B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: HDFC Bank Limited Common Stock is far larger — about 118.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and HDFC Bank Limited Common Stock pays a 1.8% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HDB | MRVI | |
|---|---|---|
Market Cap | $114.94B | $972.90M |
Volume | 6,516,078 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $37.18 | $9.00 |
52-Week Low | $21.84 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.23T | $1.08B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDFC Bank (HDB) trades at $22.76, up 0.8% with neutral technical indicators. The bank maintains strong profitability with 28.24% net income margin and consistent earnings beats. However, significant legal headwinds emerge as multiple class action lawsuits approach deadlines in October 2026, creating investor uncertainty despite solid fundamentals.
While HDB demonstrates financial strength with improving debt-to-asset ratios and positive cash flow projections for 2026, the pending securities litigation represents a material risk. Analyst consensus leans cautious with 67% hold ratings, suggesting investors await legal clarity before more bullish positioning despite attractive valuation metrics.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HDFC Bank Limited Common Stock
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
